Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a Healthcare company (Biotechnology) with a market capitalization of $111M. The Maz Rating grades it against the other companies in its sector.
Akebia Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.40, Akebia Therapeutics, Inc. trades at 0.6x sales and 5.4x book value. Over the last twelve months it generated about $197M of revenue and a net loss of $44M. It runs a gross margin of 78.9%, an operating margin of -15.7% and a net margin of -22.6%. It shows return on equity of -169.2%, return on invested capital of -14.2% and a free cash flow yield of 12.4%. On the balance sheet: a debt-to-equity ratio of 2.97 and a current ratio of 1.36. Over the past 52 weeks the share price ranged from $0.36 to $1.75, with a beta of 0.23.
Akebia Therapeutics, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 7 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.